ASTRO: Oropharynx CA Survival Rates Worse With RT/Cetuximab
FRIDAY, Oct. 26, 2018 -- For patients with locoregionally advanced human papillomavirus (HPV)-related oropharynx cancer, radiation/cetuximab results in inferior overall and progression-free survival versus radiation/cisplatin, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Erbitux | Genital Warts | Human Papillomavirus (HPV) | Oropharyngeal Cancer | Pharmaceuticals | Study